Toxin-producing Gram-positive bacteria are responsible for emerging and lifethreatening infections in humans worldwide. Both rapid toxin detection and adapted therapy are essential to limit the morbidity due to such toxins, especially staphylococcal Panton-Valentine leukocidin (PVL). Here we describe the use of a mass spectrometry profile generated by matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) followed by ClinProTools TM 2.0 software analysis to find a reproducible model able to identify PVL in Staphylococcus aureus strains. Eighty-one S. aureus strains were used and tested for the presence of PVL, toxic shock syndrome toxin (TSST-1) and mecA genes. The peak at 4448 mass-to-charge ratio (m/z) was the most relevant peak to differentiate between PVL-producing and non-PVL-producing S. aureus. A model using only this peak had an overall recognition capability of 100% and an overall cross-validation of 77.07%. Prospective evaluation of the model allowed two cases of PVL-producing strains to be detected within a few minutes during the time of care and before polymerase chain reaction (PCR) results.
A c c e p t e d M a n u s c r i p t S. aureus strains were used and tested for the presence of PVL, toxic shock syndrome toxin (TSST-1) and mecA genes. The peak at 4448 mass-to-charge ratio (m/z) was the most relevant peak to differentiate between PVL-producing and non-PVL-producing S. aureus. A model using only this peak had an overall recognition capability of 100% and an overall cross-validation of 77.07%. Prospective evaluation of the model allowed two cases of PVL-producing strains to be detected within a few minutes during the time of care and before polymerase chain reaction (PCR) results.
MALDI-TOF-MS for rapid detection of staphylococcal Panton-

Valentine leukocidin
Our study represents a proof of concept for the use of such rapid technology as a point-of-care method to identify potential lethal toxin quickly. We believe that such a rapid method will be timely to help change the therapeutic strategy and could be used in the future for other pathogens and infectious diseases.
M a n u s c r i p t
Introduction
Serious complications caused by Staphylococcus aureus, one of the most significant and frequent human pathogens, are a worldwide phenomenon that concern both hospital and community settings. Toxin production contributes mainly to the pathogenicity of this bacterium. Panton-Valentine leukocidin (PVL), a twocomponent, pore-forming, cytolytic toxin that targets polymorphonuclear cells and causes cell death by necrosis or apoptosis [1] , is one of the most virulent staphylococcal toxins described. Necrotizing pneumonia [2] and necrotizing skin and soft tissue infection [3] are the predominant results due to infection by PVL-producing S. aureus strains. Because severe infection caused by strains producing PVL should benefit from a quickly adapted therapy [4] in order to decrease mortality, rapid detection of this toxin is critical.
Classical approaches for recognising PVL toxin are generally based on the immunological properties of the toxin, such as enzyme-linked immunosorbent assay (ELISA) [5] and latex agglutination [6] , or on polymerase chain reaction (PCR)-based methods [7] . These assays are costly and time-consuming methods. Recently, matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF-MS) has played an interesting role in microbiological laboratories owing to its speed, ease of use and accuracy in the identification and classification of bacteria, including S. aureus [8] , as well as its discriminatory power to differentiate between strains with different phenotypes, including the expression of antibiotic resistance [9, 10] .
This work provides a proof of concept that the spectra profiling generated by MALDI-TOF-MS could be used as a clinical microbiology strategy to identify quickly S.
aureus isolates harbouring PVL toxin and thus to adapt therapy during the time of care of the patient. 
Material and methods
Bacterial strains
Identification of Staphylococcus aureus
The isolates were first identified by conventional methods including Gram staining, catalase activity, mannitol fermentation, ability to coagulate rabbit plasma (bioMérieux, Marcy l'Etoile, France) and Pastorex Staph-Plus agglutination (bioMérieux). The identification was confirmed using the VITEK 2 Auto System (bioMérieux). Antimicrobial susceptibility testing was performed by the disk diffusion method according to the Clinical and Laboratory Standards Institute and also using VITEK 2.
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Detection of the mecA gene PVL toxin and SCCmec typing
To confirm resistance to meticillin in S. aureus isolates, the primers mecAF (5'-GTTAGATTGGGATCATAGCGTCATT) and mecAR (5'-TGCCTAATCTCATATGTGTTCCTGTAT) and the TaqMan probe mecAProbe (6FAM-TTCCAGGAATGCAGAAAGACCAAAGCAT-TAMRA) were used in this study.
Staphylococcal cassette chromosome mec (SCCmec) typing was performed as described previously [7] . For SCCmec type V, the following primers and TaqMan probe were used: cassMecVF (5'-TCTGGGAGTTCTGCCTGTCA); cassMecVR (5'-TCACATTTGACGCAATCTGCT); and cassMecVP (6FAM-TGCTGAAGTCGTCGAACGCGTAATCA-TAMRA).
All isolates were also screened by real-time PCR for the presence of PVL toxin and toxic shock syndrome toxin (TSST-1) using the primers and TaqMan probe as described previously [7, 11] .
Bacterial analysis using MALDI-TOF-MS
Strains were plated on Columbia agar with 5% sheep blood (bioMérieux) and incubated for 24 h at 37 C. One colony from each strain was harvested and deposited on a target plate (Bruker Daltonics, Bremen, Germany) in three or four replicates to minimise random effect. Two microlitres of matrix solution (saturated  cyano-4-hydroxycinnamic acid, 50% acetonitrile, 2.5% trifluoroacetic acid) was then added and allowed to co-crystallise with the sample. Analysis was performed in an MALDI-TOF-MS spectrometer (337 nm) (Autoflex; Bruker Daltonics) with the FLEX control software (Bruker Daltonics). Positives ions were extracted with an 
Results
All the isolates included in the study were first tested for the presence of PVL, TSST-1 and mecA genes as well as determination of SCCmec type. Table 1 First we compared the MALDI-TOF spectra obtained from strains harbouring the PVL gene (24 isolates) with the spectra obtained from the other S. aureus (57 isolates) using ClinProTools TM 2.0. Using Genetic Algorithm analysis, several models with a different number of peaks have been generated. Considering the P-value and standard deviation given by the software, many peaks were differentially expressed between the two groups. Two interesting peaks were 4448 m/z and 5302 m/z, which Finally, the latest model (i.e. the model with the 4448 m/z peak only) was evaluated blindly using 34 clinical S. aureus strains (Table 1) . Four spectra from each strain were generated by MALDI-TOF-MS and screened for the presence of PVL. Testing these additional strains in our model, five isolates were classified as positive strains and only two of them were later confirmed using molecular methods. Thus, this model exhibited a sensitivity of 100%, a specificity of 90.6%, a PPV of 40% and a NPV of 100%.
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Discussion
In the present study, we describe a novel, fast and inexpensive tool for discrimination of S. aureus isolates that do or do not produce PVL toxin compared with the actual methods used. Our promising method is based mainly on screening the spectrum profile of S. aureus obtained from MALDI-TOF-MS by a model generated using ClinProTools TM 2.0 software. Whilst PCR requires time, technical experience and equipped laboratories, the method described here is very easy and cheap and the analysis can be done within a few minutes.
Our results demonstrate that the peak at 4448 m/z was the most relevant peak as it was differentially expressed between PVL + and PVL -strains (P < 0.05). Interestingly, the model with only this peak had an overall recognition capability of 100% and an overall cross-validation of 77.07%. Through this model, two additional cases were detected in 3 min and before the results of PCR that were obtained during the following 24 h. It is interesting to note that four spectra for each isolate were analysed to confirm the results. The 4448 m/z peak was not found in TSST-1-producing S.
aureus. It will be interesting in the future to see whether other exotoxin-producing S.
aureus strains share this peak with PVL-associated ones
The predacious infection caused by strains producing PVL and the high mortality (ca.
75% in the case of necrotizing pneumonia [12] ) increase the need for quick detection of such strains. In fact, an appropriate antimicrobial treatment should be administered as soon as possible if a patient is likely to be infected by PVL-associated S. aureus.
For example, it has been demonstrated that subinhibitory concentrations of oxacillin, an antibiotic frequently used in the treatment of meticillin-sensitive S. aureus, can M a n u s c r i p t enhance PVL production [13] , whilst PVL induction is suppressed with a combination of oxacillin and another antibiotic such as clindamycin, rifampicin or linezolid [13] .
Recently it has been demonstrated that protein synthesis inhibitors such as clindamycin can suppress the translation of toxin genes and may have a favourable effect on infections caused by exotoxin-producing S. aureus [14] . On the other hand, intravenous immunoglobulin administration, as an adjunct to antimicrobials, has been found to improve clinically patients with PVL-associated pneumonia [4, 15] . This latter essential therapy can neutralise pore formation and inhibit the cytopathic effect of PVL toxin [12] that is already produced and present in the lung substance with concomitant tissue damage [4] . Taken together, the high mortality rate of PVLassociated infections and the beneficial effect of early adapted therapy make the time to report results to physicians a critical point as they are likely to change the therapeutic strategy based on the knowledge of whether the strain produces PVL or not. Thus, a rapid method for predicting the presence of PVL toxin could be a critical tool even if the specificity is not 100%.
It is also important that these preliminary results should be expanded and confirmed with more strains obtained from different countries and/or using different conditions of culture and MS instruments.
In conclusion, we demonstrated as a proof of concept that MALDI-TOF-MS is a powerful tool to detect PVL-producing S. aureus rapidly. We believe that this methodology could replace conventional methods used in clinical microbiology for rapid identification of bacterial virulence factor and/or antibiotic resistance determinants, allowing changes in therapeutic strategies during time of care.
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